1. Home
  2. CSTL vs NPKI Comparison

CSTL vs NPKI Comparison

Compare CSTL & NPKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSTL
  • NPKI
  • Stock Information
  • Founded
  • CSTL 2007
  • NPKI 1932
  • Country
  • CSTL United States
  • NPKI United States
  • Employees
  • CSTL N/A
  • NPKI N/A
  • Industry
  • CSTL Medical Specialities
  • NPKI Metal Fabrications
  • Sector
  • CSTL Health Care
  • NPKI Industrials
  • Exchange
  • CSTL Nasdaq
  • NPKI Nasdaq
  • Market Cap
  • CSTL 576.3M
  • NPKI 527.6M
  • IPO Year
  • CSTL 2019
  • NPKI N/A
  • Fundamental
  • Price
  • CSTL $19.78
  • NPKI $5.95
  • Analyst Decision
  • CSTL Strong Buy
  • NPKI Strong Buy
  • Analyst Count
  • CSTL 6
  • NPKI 1
  • Target Price
  • CSTL $40.00
  • NPKI $12.00
  • AVG Volume (30 Days)
  • CSTL 403.1K
  • NPKI 864.1K
  • Earning Date
  • CSTL 05-01-2025
  • NPKI 05-01-2025
  • Dividend Yield
  • CSTL N/A
  • NPKI N/A
  • EPS Growth
  • CSTL N/A
  • NPKI N/A
  • EPS
  • CSTL 0.62
  • NPKI N/A
  • Revenue
  • CSTL $332,069,000.00
  • NPKI $217,489,000.00
  • Revenue This Year
  • CSTL N/A
  • NPKI $11.74
  • Revenue Next Year
  • CSTL $6.01
  • NPKI $12.06
  • P/E Ratio
  • CSTL $32.29
  • NPKI N/A
  • Revenue Growth
  • CSTL 51.09
  • NPKI 4.74
  • 52 Week Low
  • CSTL $16.97
  • NPKI $5.33
  • 52 Week High
  • CSTL $35.84
  • NPKI $8.65
  • Technical
  • Relative Strength Index (RSI)
  • CSTL 36.62
  • NPKI N/A
  • Support Level
  • CSTL $19.22
  • NPKI N/A
  • Resistance Level
  • CSTL $20.30
  • NPKI N/A
  • Average True Range (ATR)
  • CSTL 0.81
  • NPKI 0.00
  • MACD
  • CSTL 0.23
  • NPKI 0.00
  • Stochastic Oscillator
  • CSTL 43.33
  • NPKI 0.00

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, among others. The company's test portfolio consists of test offerings to aid clinicians in the diagnosis and treatment of cancers or precancerous diagnoses in the fields of dermatology, gastroenterology, and ophthalmology and a pharmacogenomics ("PGx") test to guide optimal drug treatment for patients diagnosed with depression, anxiety, and other mental health conditions.

About NPKI NPK International Inc. Common Stock

NPK International Inc Formerly Newpark Resources Inc is a diversified supplier providing environmentally-sensitive products, as well as rentals and services to customers across multiple industries. The company has two operating segments: Industrial Solutions and Fluids Systems. Fluids Systems segment which generates the majority of the revenue, provides drilling, completion, and stimulation fluids products and related technical services to customers for oil, natural gas, and geothermal projects. Geographically, the company derives majority of its revenue from the United States and also has its presence in Canada, EMEA, Latin America, and Asia Pacific regions.

Share on Social Networks: